Pacific Edge Limited (“PEB”) – Trading Halt of Securities

NZX Limited
Level 2, NZX Centre
11 Cable Street
PO Box 2959
Wellington 6140
New Zealand
Tel +64 4 472 7599

www.nzx.com

Memorandum

To:
Market Participants
From:
NZX Product Operations
Date:
Friday, 20 February 2026
Subject
: Pacific Edge Limited (“PEB”) – Trading Halt of Securities


Message
:
NZ RegCo advises that, at the request of Pacific Edge Limited (“PEB”), it has placed a trading
halt on PEB ordinary shares. The trading halt was placed at pre-market open today.

Attached is the trading halt application, for further information.

Please contact NZX Product Operations on +64 4 496 2853 or productoperations@nzx.com
with any queries.

ENDS

---

20 February 2026
Page 1 of 2



To: ASX Limited
Level 27
39 Martin Place
Sydney NSW 2000
Australia
TradingHaltsNZ@asx.com.au
NZ RegCo
11 Cable St
Wellington
New Zealand
issuer@nzregco.com

Request for trading halt: Pacific Edge ASX Code: PEB; NZX Code: PEB
We request a trading halt to be applied to our securities (ISIN: NZPEBE0002S1) under ASX Listing Rule
17.1 and NZX Listing Rule 9.9.1(a) and set out details of the request below as per the rules of each of
ASX and NZX.
We would like the trading halt to commence from: prior to the market open today (Friday 20 February
2026).
Reasons for trading halt: Novitas, Pacific Edge’s Medicare Administrative Contractor (MAC) is scheduled
to hold a Contractor Advisory Committee (CAC) meeting commencing at 6pm on 19 February 2026, US
ET (today, Friday 20 February 2026, 12:00pm NZST), a time when Pacific Edge’s shares would normally
be trading on both the NZX and ASX.
The meeting, between Novitas and urological experts, is to be held in public and will be streamed online.
It has been convened to discuss “evidence for the use of urine-based biomarkers in patients with
microhematuria” and is designed to systematically capture expert opinion on the subject. Because CACs
are generally convened ahead of developing new or substantially revised medical policy as a draft Local
Coverage Determination (LCD), the content of the meeting (and its outcome) may have significant strategic
implications for the future of Pacific Edge.
Specifically, comments made by experts or Novitas personnel during the meeting regarding the general
utility of biomarkers for hematuria evaluation, the appropriate patient types and what physicians should do
with a test result (among other things) could be indicative of whether the MAC is minded to develop a draft
LCD supporting Medicare reimbursement of Cxbladder (or leave Cxbladder’s current Medicare status
unchanged as not eligible for reimbursement).
Pacific Edge therefore believes it is appropriate for trading in its shares to cease during the meeting and
until the company has had time to assess its content and prepare an announcement that provides context
to investors.

Page 2 of 2
How long we want the trading halt to last: Until the earlier of PEB releasing a statement to the market
regarding the CAC meeting, or the commencement of trading on the NZX on Tuesday, 24 February 2026.
However, Pacific Edge expects to release this statement ahead of the market open on Monday 23
February 2026.
The event we expect to happen that will end the trading halt: The release of a statement to the market
regarding the CAC meeting.
Other information necessary to inform the market about the trading halt or that ASX or NZ RegCo
have requested. N/A
We confirm that we are not aware of any reason why the trading halt should not be granted.
Yours sincerely


Grant Gibson
Chief Financial Officer
Pacific Edge Limited